Saltar al contenido
Merck

DNA methylation and expression of KCNQ3 in bipolar disorder.

Bipolar disorders (2014-07-22)
Zachary Kaminsky, Ilenna Jones, Ranjana Verma, Lena Saleh, Hersh Trivedi, Jerry Guintivano, Ryan Akman, Peter Zandi, Richard S Lee, James B Potash
RESUMEN

Accumulating evidence implicates the potassium voltage-gated channel, KQT-like subfamily, member 2 and 3 (KCNQ2 and KCNQ3) genes in the etiology of bipolar disorder (BPD). Reduced KCNQ2 or KCNQ3 gene expression might lead to a loss of inhibitory M-current and an increase in neuronal hyperexcitability in disease. The goal of the present study was to evaluate epigenetic and gene expression associations of the KCNQ2 and KCNQ3 genes with BPD. DNA methylation and gene expression levels of alternative transcripts of KCNQ2 and KCNQ3 capable of binding the ankyrin G (ANK3) gene were evaluated using bisulfite pyrosequencing and the quantitative real-time polymerase chain reaction in the postmortem prefrontal cortex of subjects with BPD and matched controls from the McLean Hospital. Replication analyses of DNA methylation findings were performed using prefrontal cortical DNA obtained from the Stanley Medical Research Institute. Significantly lower expression was observed in KCNQ3, but not KCNQ2. DNA methylation analysis of CpGs within an alternative exonic region of KCNQ3 exon 11 demonstrated significantly lower methylation in BPD, and correlated significantly with KCNQ3 mRNA levels. Lower KCNQ3 exon 11 DNA methylation was observed in the Stanley Medical Research Institute replication cohort, although only after correcting for mood stabilizer status. Mood stabilizer treatment in rats resulted in a slight DNA methylation increase at the syntenic KCNQ3 exon 11 region, which subsequent analyses suggested could be the result of alterations in neuronal proportion. The results of the present study suggest that epigenetic alterations in the KCNQ3 gene may be important in the etiopathogenesis of BPD and highlight the importance of controlling for medication and cellular composition-induced heterogeneity in psychiatric studies of the brain.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Cloruro de litio, ACS reagent, ≥99%
Sigma-Aldrich
Cloruro de litio, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
Cloruro de litio, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Cloruro de litio, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride solution, 8 M, Molecular Biology, ≥99%
Sigma-Aldrich
Cloruro de litio, Molecular Biology, ≥99%
Sigma-Aldrich
Cloruro de litio, powder, ≥99.98% trace metals basis
Supelco
Electrolyte solution, nonaqueous, 2 M LiCl in ethanol
Sigma-Aldrich
Sodium bisulfite solution, purum, ~40%
Supelco
Lithium chloride solution, 1 M in ethanol
Sigma-Aldrich
Cloruro de litio, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
Cloruro de litio, BioUltra, Molecular Biology, anhydrous, ≥99.0% (AT)
Sigma-Aldrich
1-Decanethiol, 96%
Sigma-Aldrich
Cloruro de litio, puriss. p.a., anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Cloruro de litio, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Sigma-Aldrich
Cloruro de litio, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
1-Decanethiol, 99%
Sigma-Aldrich
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Lithium chloride solution, 2 M in ethanol